Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares may be establishing a bottom as WBA has bounced off of the $30 lows and is trading at less than 15x its FCF. Walgreens is executing its turnaround plan, growing the U.S. business, and has a strong outlook over the next several years.

Walgreens: Shares May Be Establishing A Bottom After A Q4 Beat

Walgreens Boots Alliance is a company in transition. It had ventured into the local clinical care business. It had embarked on Cost Transformation Program whose benefits have yet to be fully realized. There is a strong operating track record to suggest that it would be successful in its transformation. It is also financially strong to give it time to realize the results.

Walgreens Boots Alliance - A Company In Transition

Walgreens Boots Alliance executives said during their earnings call Thursday that pharmacy staffing shortages have created challenges for prescription growth.

Walgreens says staffing shortages hit prescription growth

Walgreen's Boots Alliance is up sharply after posting a double beat. But with growth remaining sluggish, this current bump in WBA stock mayl be short lived

The Rally in Walgreen's Boots Alliance May be Short Lived

Salesforce

Microsoft

The Dow Jones Industrial Average gets too much credit as a barometer for the overall stock market. That job belongs to the S&P 500.

3 Dow Stocks to Buy if You Are Feeling Greedy

Walgreens Boots Alliance WBA, +5.92% is doubling down on its big healthcare bet as the pharmacy giant upped a long-term sales target for its growing healthcare business and described its plans to become a leader in the American medical system.

Walgreens gets serious about its move into healthcare

Walgreens Boots Alliance, Inc. (NASDAQ:WBA ) Q4 2022 Results Conference Call October 13, 2022 8:30 AM ET Company Participants Tiffany Kanaga - VP, Global IR Roz Brewer - CEO James Kehoe - CFO John Driscoll - President, U.S. Healthcare Rick Gates - SVP, Pharmacy and Healthcare at Walgreens Conference Call Participants Lisa Gill - JP Morgan Elizabeth Anderson - Evercore ISI Steven Valiquette - Barclays Charles Rhyee - Cowen Ann Hynes - Mizuho Securities George Hill - Deutsche Bank Michael Cherny - Bank of America Kevin Caliendo - UBS A.J. Rice - Credit Suisse Eric Percher - Nephron Research Erin Wright - Morgan Stanley John Ransom - Raymond James Operator Good morning.

Walgreens Boots Alliance, Inc. (WBA) Q4 2022 Earnings Call Transcript

The U.S. Healthcare segment of Walgreens Boots (WBA) grows on key contract wins, continued partnership growth and a strong focus on execution.

Walgreens Boots (WBA) Q4 Earnings Top, Operating Loss Concerns

Taiwan Semiconductor Manufacturing

Keep your eyes on key companies during earnings season.

These 2 Stocks Could Lead a Year-End Market Rally

In what could be characterized as the latest entry in the “COVID Changed Everything” file, Walgreens Boots Alliance said Thursday that it is simplifying its operations under three business segments as part of its transformation to become a ‘Consumer-Centric Healthcare' company.

Walgreens Charts Simplified Future as ‘Consumer-Centric Healthcare' Company

Walgreens (WBA) delivered earnings and revenue surprises of 2.56% and 0.13%, respectively, for the quarter ended August 2022. Do the numbers hold clues to what lies ahead for the stock?

Walgreens Boots Alliance (WBA) Beats Q4 Earnings Estimates

Source: saaton / Shutterstock.com Walgreens (NASDAQ: WBA ) stock is gaining in on Thursday following the release of the pharmacy company's earnings report for its fiscal fourth quarter of 2022. The Walgreens earnings report starts with adjusted earnings per share of 80 cents.

Walgreens (WBA) Stock Pops on Q4 Earnings Beat

Walgreens reports adjusted earnings of 80 cents a share its fiscal fourth quarter, down 31.8% from the same quarter last year, but above consensus estimates of 77 cents.

Walgreens Stock Rises on Slight Earnings Beat

National Retail Properties

Realty Income Corp

Verizon

Exxon Mobil

Global X S&P 500 Covered Call ETF

The Dividend Harvesting Portfolio is now generating $613.17 in annual dividends yielding 8.25%. The Dividend Harvesting portfolio has an 83.33% record of finishing the week in the black since its inception, 70/84 weeks.

Dividend Harvesting Week 84 Update: $8,400 Allocated, $613.17 In Annual Dividends Yielding 8.25% Across 77 Positions

Walgreens Boots Alliance reported a $415 million loss thanks in part to higher expenses related to a major global “cost management program.”

Walgreens Reports $415 Million Loss On Higher Tab For Cost Management Effort

The drugstore chain's fiscal fourth-quarter sales dropped 5.3% with a larger decline in U.S. pharmacy business

Walgreens Quarterly Sales Fall on Fewer Prescriptions, Covid-19 Vaccinations

Shares of Walgreens Boots Alliance Inc. WBA, -2.05% jumped 5.5% in premarket trading Thursday, after the drug store and healthcare services company reported fiscal fourth-quarter profit and sales that fell but topped expectations, and raised its long-term target for its U.S. Healthcare business. On a net basis, the company swung to a loss of $415 million, or 48 cents a share, for the quarter to Aug. 31, from income of $627 million, or 72 cents a share, in the year-ago period.

Walgreens stock jumps as profit and sales fall but beat expectations, long-term U.S. Healthcare targets raised

Walgreens' profit outlook for the new fiscal year is largely in line with Wall Street's expectations.

Walgreens beats sales expectations, as it expands its health-care business

Walgreens Boots Alliance Reports Fiscal Year 2022 Earnings

Walgreens Now Offering Updated COVID-19 Booster Appointments for Children Ages 5+

Walgreens Boots Alliance (WBA) is gearing up for its fiscal fourth-quarter earnings report, due out before tomorrow's open, in which analysts expect profits of 77 cents per share.

Walgreens Boots Alliance Prepares For Quarterly Earnings

Walgreens Boots Alliance (NASDAQ: WBA) is scheduled to report its fiscal Q4 2022 results on Thursday, October 13.

What To Expect From Walgreens Stock As It Reports Its Q4 Results?

Walgreens Boots Alliance is buying the rest of the post acute and home care company CareCentrix for $392 million.

Walgreens To Buy The Rest Of CareCentrix Home Care For $392 Million

DEERFIELD, Ill.--(BUSINESS WIRE)--WBA announced acceleration of its plans to acquire full ownership of CareCentrix (CCX Next, LLC), advancing its healthcare long-term growth strategy.

Walgreens Boots Alliance Accelerates Full Acquisition of CareCentrix

Blackrock Inc

Delta Air Lines

The three major U.S. equity indexes closed lower again Monday. The Dow Jones industrials ended the day down 0.32%, the S&P 500 closed 0.75% lower and the Nasdaq retreated 1.04%.

News for Walgreens Stock (WBA)